Ozempic is here, but is it affordable for most Indians?

Walk into any clinic today and you’ll hear the same concern from people managing diabetes: “Is there something easier and more effective?” That’s where Ozempic steps in. Newly launched in India, this once-weekly injection has become a global sensation for its dual role in blood sugar control and weight management.

But in India, where most people pay for medicines out of their own pocket—the biggest question isn’t about how it works, but whether it fits into a monthly budget.

Ozempic mimics the hormone GLP-1 (glucagon-like peptide-1), helping the body release insulin, slow digestion and reduce appetite.

While its Indian approval is specifically for diabetes management, its wider global use for weight-linked conditions has pushed up demand. In several countries, semaglutide medicines have also shown benefits for heart and kidney health.

But with its arrival, important questions arise: How much does it cost? Is it affordable? How does it compare with other GLP-1 drugs? And what will happen to pricing once generics enter the market? Understanding these points matters deeply for patients and caregivers navigating India’s growing metabolic health challenges.

How much does Ozempic cost in India?

In December 2025, Novo Nordisk officially introduced Ozempic in India, with the following pricing:

• 0.25 mg pen: Rs 8,800 (about Rs 2,200 per week)
• 0.5 mg pen: Rs 10,170 (about Rs 2,542 per week)
• 1 mg pen: Rs 11,175 (about Rs 2,793 per week)

Each pre-filled pen provides four weekly doses, and doctors prescribe the strength based on the patient’s clinical needs.

The company says these are “India-tailored prices” aimed at improving access compared with high-income countries. Even so, the cost remains high for many, especially when several pens are needed each month.

According to NDTV Profit, patients on typical doses like 0.5 mg or 1 mg may spend around Rs 10,000–Rs 11,000 per month, which adds up to Rs 40,000–Rs 45,000 per year, excluding consultations and tests.

Why is pricing such an important factor?

With more than 100 million adults living with diabetes, out-of-pocket spending is common in India. Many patients already pay for medicines, lab tests and long-term complications. As a result, the cost of treatment becomes a major barrier to consistency, especially with chronic conditions that require lifelong care.

How does Ozempic compare with other GLP-1 medicines?

Ozempic is not the only GLP-1 receptor agonist available in India. Other options include:

Mounjaro (tirzepatide) – Approved for diabetes and weight management. Monthly costs usually fall between Rs 14,000 and Rs 17,500 in certain formulations. While some patients may experience greater weight-loss effects, it is still more expensive than standard Ozempic doses.

Wegovy (semaglutide 2.4 mg) – Intended specifically for obesity. Reports suggest Indian prices range from Rs 17,345 to over Rs 26,000 per month (The Economic Times).

So although Ozempic may be relatively more affordable than some higher-dose obesity medications, the overall cost is still steep for many households.

What does Ozempic cost weekly, monthly and yearly?

Weekly and monthly costs:

• Starter dose (0.25 mg) – around Rs 2,200 per week (Rs 8,800 monthly)
• Mid-range dose (0.5 mg) – around Rs 10,170 per month
• Higher dose (1 mg) – around Rs 11,175 per month

These are the direct pharmacy prices and do not include doctor visits, tests or private-sector fees.

Annual spending

At current pricing, yearly treatment expenses can cross Rs 100,000. Since most insurance plans in India do not cover outpatient prescriptions, patients often need to plan these costs themselves, along with other diabetes medications.

Will costs fall when generics arrive?

A major long-term factor is patent expiry. Semaglutide’s main patent ended in September 2024, while a secondary formulation patent lasts until March 2026. After this, generic versions are expected to enter the Indian market.

Industry experts anticipate significant price drops once generics launch, typically 30–50% lower at the start, and potentially even more once competition strengthens.

However, the availability of generics depends on approval processes, production capacity and how Indian pharmaceutical companies price their products.

Is Ozempic worth the cost?

Blood sugar control

Ozempic is approved in India as an add-on to diet and exercise for type-2 diabetes. It helps lower HbA1c and maintain blood sugar targets, with the convenience of once-a-week dosing.

Weight management

Although Ozempic itself is not approved for weight loss in India, semaglutide has shown appetite-reducing and weight-related benefits for people with diabetes. Higher-dose versions like Wegovy are approved internationally for obesity.

Heart and kidney benefits

Clinical trials have shown cardiovascular and kidney protection in people with diabetes, giving it an edge over some older glucose-lowering medicines. Many global guidelines support GLP-1 receptor agonists for those at high cardiovascular risk.

What should patients consider before starting Ozempic?

• Seek advice from an endocrinologist or diabetologist to decide on suitable dosing and track progress.
• Explore insurance options, as some employer or private health plans may cover part of the cost.
• Consider long-term budgeting, as additional expenses include tests, consultations and follow-up care.
• Keep an eye on upcoming generic semaglutide, expected after 2026, which could lower costs significantly.

(Disclaimer: This article is for informational purposes only and should not be considered medical advice. Patients should consult a qualified healthcare professional before starting, changing or stopping any medication)